Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis

• by Ejike Daniel Eze, Leopold Ntakirutimana, Swase Dominic Terkimbi, Muluken Walle, Abdullahi Hussein Umar, Diresibachew Haile Wondimu, Makinde Vincent Olubiyi, Onyinye Cynthia Okeke, Olufunke Onaadepo, Jimoh Abdulazeez, David Chibuike Ikwuka, Elemi John Ani, Abdullateef Isiaka Alagbonsi

• July 14, 2026

This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

• August 31, 2026

• 5 min

Coding for Ocular Tumors

Ocular tumor coding can be challenging because ocular oncology often involves evolving lesions, diagnostic uncertainty, and terminology that does not always translate cleanly into ICD-10-CM codes. Understanding how to distinguish benign, malignant, in situ, and uncertain histologic behavior neoplasms is essential for accurate coding, medical necessity, and audit defensibility.

• by Elizabeth Cifers, MBA, MSW, CHC, CPC

• September 1, 2026

• 4 min

Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features

• by Si Li, Xue Cheng, Ronggui Xing, Zhenyin Peng, Tianyou Xiong, Yanan Jiang, Xianbiao Zou

• August 31, 2026